부산대학교 도서관

Carlos Mario Balcázar-Valencia,1 Andrés Felipe García-Ramos,2– 5 Luis Miguel Osorio-Toro,2,3,6 Yessica Alejandra Ordoñez-Guzmán,3 Nathalia Buitrago-Gómez,4 William Fernando Cabarcas-López,7 Carlos Javier Vizcaino-Guerrero,8 Jorge Enrique Daza-Arana,2,9 Alex Ramírez-Rincón,4 Katherine Restrepo-Erazo2,10 1Specialization in Internal Medicine, Faculty of Health Sciences, Universidad Libre, Santiago de Cali, Colombia; 2Specialization in Internal Medicine, Faculty of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia; 3Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia; 4Specialization in Endocrinology, Faculty of Health Sciences, Universidad Pontificia Bolivariana, Medellín, Colombia; 5Specialization in Internal Medicine, Faculty of Health, Universidad del Valle, Santiago de Cali, Colombia; 6Genetics, Physiology and Metabolism Research Group (GEFIME), Faculty of Health Sciences, Universidad Santiago de Cali, Santiago de Cali, Colombia; 7Master in Epidemiology, Faculty of Health, Universidad de Caldas, Manizales, Colombia; 8Specialization in Endocrinology, Faculty of Health, Fundación Universitaria Ciencias de la Salud FUCS, Bogotá, Colombia; 9Health and Movement Research Group, Faculty of Health Sciences, Universidad Santiago de Cali, Santiago de Cali, Colombia; 10Specialization in Endocrinology, Faculty of Health, Universidad Nacional de Colombia, Bogotá D.C., ColombiaCorrespondence: Jorge Enrique Daza-Arana, Specialization in Internal Medicine, Faculty of Health, Universidad Santiago de Cali, Calle 5 # 62-00, Santiago de Cali, Colombia, Tel/Fax +57 3108923676, Email jorge.daza01@usc.edu.coPurpose: Diabetes is a public health problem that requires strategies to impact glycemic control and reduce the risk of long-term medical complications. Pharmacological management is a necessary treatment for this disease. Therefore, semaglutide is an essential tool to achieve the treatment targets. The present study aimed to evaluate the semaglutide effects on a cohort with type 2 diabetes mellitus (T2DM) in Colombia.Materials and Methods: The cohort included 49 patients with T2DM that have been treated in a specialized care center. Their glycemic outcomes, weight, renal function, and adverse events were evaluated through a 3-, 6- and 12-month follow-up.Results: Significant differences were observed in the outcome evaluation: reduction of glycated hemoglobin levels (MD − 2.74 CI − 1.95 to − 3.52 in 6 months), fasting plasma glucose levels, body weight (MD − 7.11 CI − 5.97 to − 8.24), and the albumin-to-creatinine ratio. The results were maintained throughout the treatment period. The adverse event rate was 16.3%, predominating gastrointestinal events.Conclusion: This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM.Keywords: semaglutide, diabetes mellitus, glycated hemoglobin A, obesity, glycemic control